News & Updates
Filter by Specialty:
Can an antibody-drug conjugate alter the treatment landscape of difficult-to-treat ovarian cancer?
20 Apr 2023
byAudrey Abella
Mirvetuximab soravtansine (MIRV), an antibody drug conjugate (ADC), showed antitumour activity in women with platinum-resistant ovarian cancer* (PROC) with high folate receptor alpha (FRα) expression, findings from the phase III SORAYA study have shown.
Can an antibody-drug conjugate alter the treatment landscape of difficult-to-treat ovarian cancer?
20 Apr 2023
Maximal transurethral resection tied to better outcomes at cystectomy
19 Apr 2023
Pathological response at cystectomy may improve with maximal resection in patients undergoing transurethral resection for muscle-invasive bladder cancer prior to neoadjuvant chemotherapy, according to a study.
Maximal transurethral resection tied to better outcomes at cystectomy
19 Apr 2023
Investigational imaging agent holds promise for diagnosing renal cancer
17 Apr 2023
byAudrey Abella
In the pivotal phase III ZIRCON study, PET/CT imaging with 89Zr-DFO-girentuximab, an investigational imaging agent, demonstrated potential in the noninvasive identification of clear-cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses (IDRM).